Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
61 /100
HIGH RISK
Score updated Oct 13, 2026

LYEL — Lyell Immunopharma, Inc. Dilution Risk Tracker

Track LYEL dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track LYEL — Get alerts when the score changes →

As of October 13, 2026, Lyell Immunopharma, Inc. (LYEL) has a DilutionWatch DilutionScore of 61/100, rated HIGH dilution risk. Lyell Immunopharma, Inc. has a market capitalization of $202.66M, 24.51M shares outstanding, 77 institutional holders tracked.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
62
💰 Cash Runway
40
📊 Float Risk
45
⚠️ Warrant Exposure
40
🔄 Convertible Debt
40

Dilution Forecast

☀️
Clear
No significant dilution signals
model est. 5%
📉 Score Deterioration model 10%
• Score in HIGH risk zone (61/100)
🔔 Track LYEL — Get forecast alerts →

Market Data

Market Cap$202.66M
Shares Outstanding24.51M
Float10.39M
Cash$204.10M
Debt$48.85M
Short InterestN/A

Source-Backed Evidence Depth

This public preview uses stored DilutionWatch fields and linked SEC/market records only. Missing values are not estimated.

FieldCurrent ValueBasis
DilutionScore61/100DilutionWatch score record
Shares Outstanding24.51MVerified float table or market cache
Public Float10.39MVerified float table or market cache
Market Cap$202.66MMarket data cache
Cash Runway13.5 monthsDilutionWatch score inputs
Shelf CapacityNone in current score inputsSEC-derived dilution fields
ATM CapacityNone in current score inputsSEC-derived dilution fields
Outstanding WarrantsNone in current score inputsSEC-derived dilution fields

Recent source-backed SEC insight records available on this page: 7.

Recent SEC source mix: 3 1, EFFECT 1, FORM 4 2, S-3 1, XBRL 2.

The page does not infer future share issuance, financing probability, cash needs, management intent, or price impact when source fields are absent.

Institutional Holdings

QoQ: ↑ 13.6% shares (2026Q1 vs prior)
77 institutional holders · 13.07M shares
#1 ARCH Venture Management, LLC 3.25M shares
#2 GSK plc 1.51M shares
#3 VANGUARD CAPITAL MANAGEMENT LLC 1.44M shares
+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest1.26M
Days to Cover7.4
% of Float12.2%
FINRA data as of Sep 30, 2026

Recent SEC Activity

xbrl XBRL WARRANT 2025-03-11
xbrl XBRL CONVERTIBLE 2024-02-28
Form 4 INSIDER TRANSACTION 2026-07-27
Form 4 INSIDER TRANSACTION 2026-07-27
EFFECT EFFECT 2026-04-14
Full SEC filing analysis available with free account →

Recent News

No recent news available for this ticker.

Factual LYEL Dilution Snapshot

Lyell Immunopharma, Inc. (LYEL) has a DilutionScore of 61/100, rated High dilution risk. Score date: October 13, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

DilutionScore History — Last 90 Days

LYEL's DilutionScore has held steady at 61/100 (High risk) for 89 consecutive days across the tracked period.

Period Score Risk Level Duration
Jul 16 – Oct 13, 202661/100HIGH89 days

Score recalculated daily from SEC filings and market data. Sign up free for real-time score change alerts.

Share Dilution History

LYEL shares outstanding have increased 9.8% from 21.24M (Mar 2026) to 23.33M (May 2026). Each increase represents potential dilution to existing shareholders.

Date Shares Outstanding Public Float Change
May 08, 202623.33M10.39M▲ 0.12%
May 04, 202623.33M10.38M▲ 0.02%
May 01, 202623.33M10.37M▼ 25.45%
Apr 10, 202623.33M13.92M▲ 0.06%
Mar 26, 202623.31M13.91M▼ 3.39%
Mar 23, 202623.31M14.40M▲ 6.40%
Mar 22, 202623.31M13.53M▲ 1.94%
Mar 14, 202621.24M13.27M▲ 9.84%
Mar 05, 202621.24M12.08M▲ 14.29%

Share counts sourced from verified regulatory filings. Increases indicate dilution events.

Track LYEL Dilution Risk in Real-Time
DilutionWatch monitors SEC filings 24/7 and alerts you the moment LYEL files a shelf registration, ATM offering, warrant notice, or convertible note. Free tier available — no credit card required.
Start Tracking LYEL — Free
Email alert within minutes of any SEC filing Daily DilutionScore™ recalculation Score history & trend tracking Tracks 8,000+ tickers simultaneously

Related Stocks — HIGH Risk

Other HIGH dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,490+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for LYEL
LYEL FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.